Investing in People
We invest in our people and communities, prioritize safety and foster an inclusive culture that ensures personal and business growth.
As a growing service provider to the pharmaceutical and biopharma sector, we recognize our role in advancing human health with our customers and for patients, while ensuring that our operations align with the well-being of our employees, communities, and the planet. From reducing our environmental footprint and ensuring the highest standards of product safety to upholding ethical practices and promoting inclusion, our commitment to growth, environmental sustainability and responsible innovation is core to our mission.
Our corporate responsibility strategy and commitments represent our values in action and guide how we operate as we grow our business and achieve our mission to improve and save the lives of patients. We report on the impact of our corporate responsibility strategy in alignment with global ESG standards.
We developed this strategy by integrating the perspectives of our stakeholders–employees, customers, patients and communities–who helped us identify our key priorities:
Our corporate responsibility strategy tightly aligns with our values and is integrated into our strategic plan.
We invest in our people and communities, prioritize safety and foster an inclusive culture that ensures personal and business growth.
We innovate for patients, maintaining an uncompromising focus on quality, compliance, efficiency and excellence in delivery.
We seek to minimize impact on the environment, securing a healthier, sustainable future.
We put people first. At Veranova, we know that breakthrough innovations come from creative environments that attract and inspire diverse talent and experiences, promote the respectful challenging of ideas, and encourage new and critical thinking.
We have a priority focus on health and safety (H&S), demonstrating our care and prioritization of our greatest resource, our colleagues. We continually seek to strengthen our H&S management system and tools, invest in even more training, and continue to meet our goals of reduced incidents and injuries.
Our mission to improve and save the lives of patients is strengthened by a commitment to fostering a business where inclusion is at the heart of our values, culture and operations. We are dedicated to ensuring that inclusion is not just an aspiration but a demonstrable part of our daily operations and outcomes.
Our journey starts with our strategic actions, with the aim of energizing the entire organization while encouraging diverse representation and engagement:
Inclusion at Veranova
As a critical partner to biopharmaceutical companies across the globe, we strive to operate in a way that helps sustain healthy people and a healthy planet.
In 2024, our Board of Directors approved our first corporate responsibility strategy, with environmental sustainability as a core component.
Our sustainability strategy goes beyond compliance with environmental regulations; our goal is to actively minimize the environmental impact of both our operations and products. To achieve this, we will focus on key areas including:
We are committed to continuously improving operational efficiency and integrating sustainability into all aspects of our business. This includes identifying and seizing opportunities for greater efficiency while ensuring that our product development and manufacturing processes are more environmentally sensitive.
By rigorously “greening” our processes, we aim to drive innovation, reduce environmental impacts, and contribute positively to the planet.
Leading and driving this effort is an internal sustainability committee that will report regularly to the CEO. The corporate responsibility strategy, including environmental sustainability, will be reviewed regularly by the Board of Directors.
To date, we have benchmarked our Scope 1 and 2 greenhouse gas emissions, water use and waste profile, as a baseline. In 2025 we will conduct the assessments necessary to identify where and how we can most effectively decrease our impact in these areas, starting with energy use and management. We will set and publish environmental targets in 2025.
For more information on our sustainability efforts, please email sustainability@veranova.com.
We uphold the highest standards of ethics and conduct in everything we do, and we expect our employees, anyone doing business for or with Veranova, and others acting on our behalf to do the same.
If you have questions or concerns about an ethical situation or business conduct at Veranova, our Speak Up portal and helpline allow for confidential and anonymous reporting and is available to all employees, business partners and the general public. Users will be assured confidentiality to the limit of the law and subject to the Company’s need to investigate and take appropriate action with respect to suspected violations of the Veranova Code.
The Speak Up Helpline is administered through an independent third party called Convercent, by OneTrust: Toll‐Free Speak Up Helpline: US: (800) 461-9330
UK: 0-(808)-189-1053
Online reporting portal: www.convercent.com/report
The Veranova Leadership Team (VLT), led by the CEO and including the functional leaders of the Company, are responsible for delivering on the corporate responsibility strategy. The Chief Human Resources Officer (CHRO) is the primary lead for coordinating the various elements of the strategy and holding internal site and functional leaders responsible for achieving their goals. The CEO and CHRO report progress against the corporate responsibility strategy at least twice a year to our Board of Directors.
Veranova maintains an internal Inclusion Council, composed of employee volunteers who inform the community engagement, employee engagement and organizational inclusion elements of the corporate responsibility strategy and goals, including volunteering and philanthropy. The Inclusion Council meets at least once a quarter and is responsible for providing feedback to the VLT and organizing events for employees to promote various aspects of our culture.
Our corporate responsibility strategy was formally adopted by our Board in 2024. We will report on progress against a baseline and goals annually, starting in 2025. Please email sustainability@veranova.com with any questions.
By selectively delivering highly potent APIs to cancer cells, they offer a range of improved patient outcomes, including reduced side effects and higher drug tolerability.
Cocrystals play an increasingly vital role in drug development, with specialist techniques required to identify and develop them.
Continuous manufacturing offers several advantages over traditional batch manufacturing, including increased efficiency, reduced waste, and improved product quality.
Discover new ways to advance your science with Veranova.
Contact us